Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec 29;12(3):2210-2219.
doi: 10.1002/fsn3.3900. eCollection 2024 Mar.

Tissue distribution and pharmacokinetics of isoxanthohumol from hops in rodents

Affiliations

Tissue distribution and pharmacokinetics of isoxanthohumol from hops in rodents

Rie Mukai et al. Food Sci Nutr. .

Abstract

Vegetables and fruits contain prenylflavonoids with biological functions that might improve human health. The prenylflavonoid isoxanthohumol (IXA) and its derivative, 8-prenylnaringenin (8-PN), have beneficial activities, including anti-cancer effects and suppression of insulin resistance. However, their pharmacokinetic profile is unclear. Previous studies suggested flavonoids have low systemic availability and are excreted via the feces. Therefore, this study investigated the tissue distribution dynamics of high-purity IXA (>90%) from hops administered orally, either singly (50 mg/kg body weight [BW]) or daily for 14 days (30 mg/kg BW), to mice. High-pressure liquid chromatography demonstrated that IXA was absorbed rapidly after a single administration and reached plasma maximum concentration (C max) (3.95 ± 0.81 μmol/L) by 0.5 h. IXA was present at high levels in the liver compared with the kidney, pancreas, lung, skeletal muscle, spleen, thymus, and heart. The highest IXA level after 14 days of IXA ingestion was observed in the liver, followed by the kidney, thymus, spleen, lung, and brain. There was no significant difference in IXA accumulation in tissues between the single and multiple dose groups. Analyses of the livers of rats treated with different concentrations of IXA (112.5-1500 mg/kg BW) once a day for 28 days demonstrated that IXA accumulated dose-dependently with a correlation coefficient of .813. The accumulation of 8-PN was dependent on the intake period but not the intake amount of IXA (correlation coefficient -.255). In summary, IXA and 8-PN were detected in tissues and organs up to 24 h after ingestion, suggesting that orally ingested IXA might have health benefits as a nutraceutical.

Keywords: 8‐prenylnaringenin; bioavailability; flavanone; hop flavonoid; phytoestrogen; prenylflavonoid.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

FIGURE 1
FIGURE 1
Biotransformation from IXA to 8‐PN.
FIGURE 2
FIGURE 2
IXA and 8‐PN concentrations in plasma and tissues after a single intragastric ingestion of IXA to mice (50 mg/kg BW). IXA (vertical axis on the left line) and 8‐PN (vertical axis on the right line) values determined by HPLC are the sum of aglycone and conjugated metabolites extracted from tissues with deconjugation treatment. Closed circle: IXA; open triangle: 8‐PN. The closed triangular arrows indicate the C max of IXA, and the open triangular arrows indicate the C max of 8‐PN. The data are presented as the mean + SEM, n = 4. Spleen values were measured at 4 h (n = 3).
FIGURE 3
FIGURE 3
IXA and 8‐PN accumulation in the liver after intragastric IXA administration of the indicated dose to rats for 28‐days. IXA (a) and 8‐PN (b) values determined by HPLC are the sum of aglycone and conjugated metabolites extracted from tissues with deconjugation treatment. The data are presented as the mean ± SEM (n = 7). Different letters indicate statistically significant differences among each dose (p < .05).

Similar articles

Cited by

References

    1. Alert, O. (2005). Guidance for industry estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER).
    1. Bai, H. H. , Xia, T. S. , Jiang, Y. P. , Xu, W. M. , Xu, P. C. , Wang, N. N. , Gou, X. J. , & Xin, H. L. (2022). Absorption, metabolism, and pharmacokinetic profile of xanthohumol in rats as determined via UPLC‐MS/MS. Biopharmaceutics and Drug Disposition, 43(1), 11–22. 10.1002/bdd.2306 - DOI - PubMed
    1. Bai, Y. , Peng, W. , Yang, C. , Zou, W. , Liu, M. , Wu, H. , Fan, L. , Li, P. , Zeng, X. , & Su, W. (2020). Pharmacokinetics and metabolism of Naringin and active metabolite Naringenin in rats, dogs, humans, and the differences between species. Frontiers in Pharmacology, 11, 364. 10.3389/fphar.2020.00364 - DOI - PMC - PubMed
    1. Bartmańska, A. , Tronina, T. , Popłoński, J. , Milczarek, M. , Filip‐Psurska, B. , & Wietrzyk, J. (2018). Highly cancer selective antiproliferative activity of natural prenylated flavonoids. Molecules, 23(11), 2922. 10.3390/molecules23112922 - DOI - PMC - PubMed
    1. Bei, D. , & An, G. (2016). Pharmacokinetics and tissue distribution of 5,7‐dimethoxyflavone in mice following single dose oral administration. Journal of Pharmaceutical and Biomedical Analysis, 119, 65–70. 10.1016/j.jpba.2015.11.025 - DOI - PubMed

LinkOut - more resources